Answers are grounded in this paper and cite their sources.
A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.
No takes yet. Share an insight, caveat, or question.
Schlenkhoff et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: